Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Bristol-Myers Squibb (BMY) navigates patent expirations, pipeline development, and a shifting market. FDA reviews, oncology advancements, and dividend strategies shape its future.
Bristol Myers Squibb (BMY) navigates patent expirations, oncology growth, and strategic collaborations. FDA actions and dividend appeal shape investor attention.
Bristol-Myers Squibb (BMY) navigates oncology advancements, pipeline challenges, and financial pressures. Strategic partnerships and innovation balance stability. Market rotation favors dividend stocks.
Bristol Myers Squibb navigates patent expirations with new drugs, strategic partnerships, and cost cuts. FDA reviews Opdivo/Yervoy, Breyanzi sales surge, and BioArctic collaborates.
Bristol Myers Squibb (BMY) is expanding its pipeline with strategic collaborations and robust drug data amidst competitive industry challenges.
Bristol Myers Squibb navigates pipeline advancements amid patent cliff challenges, with Opdivo, Sotyktu, and Breyanzi updates influencing investor sentiment.
Explore the latest developments, trials, and licensing agreements at BMY, impacting its competitive landscape and market outlook.
Intraday update on BMY’s breakthroughs in immuno‐oncology, robust pipeline data, and strategic financial moves.
Detailed analysis of BMY's reorganization, pipeline developments, and financial challenges amid patent expirations and a strong dividend strategy.